- Home
- STRO vs HLVX Comparison
STRO vs HLVX Comparison
Compare STRO & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- HLVX
- Stock Information
- Founded
- STRO 2003
- HLVX 2020
- Country
- STRO United States
- HLVX United States
- Employees
- STRO N/A
- HLVX N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- HLVX Health Care
- Exchange
- STRO Nasdaq
- HLVX Nasdaq
- Market Cap
- STRO 77.7M
- HLVX 83.7M
- IPO Year
- STRO 2018
- HLVX 2022
- Fundamental
- Price
- STRO $0.80
- HLVX $1.86
- Analyst Decision
- STRO Hold
- HLVX Hold
- Analyst Count
- STRO 7
- HLVX 5
- Target Price
- STRO $3.97
- HLVX $2.33
- AVG Volume (30 Days)
- STRO 833.9K
- HLVX 204.2K
- Earning Date
- STRO 08-12-2025
- HLVX 08-07-2025
- Dividend Yield
- STRO N/A
- HLVX N/A
- EPS Growth
- STRO N/A
- HLVX N/A
- EPS
- STRO N/A
- HLVX N/A
- Revenue
- STRO $66,434,000.00
- HLVX N/A
- Revenue This Year
- STRO N/A
- HLVX N/A
- Revenue Next Year
- STRO N/A
- HLVX N/A
- P/E Ratio
- STRO N/A
- HLVX N/A
- Revenue Growth
- STRO N/A
- HLVX N/A
- 52 Week Low
- STRO $0.52
- HLVX $1.34
- 52 Week High
- STRO $5.17
- HLVX $15.25
- Technical
- Relative Strength Index (RSI)
- STRO 46.11
- HLVX 52.21
- Support Level
- STRO $0.76
- HLVX $1.82
- Resistance Level
- STRO $0.94
- HLVX $2.07
- Average True Range (ATR)
- STRO 0.07
- HLVX 0.07
- MACD
- STRO -0.01
- HLVX -0.01
- Stochastic Oscillator
- STRO 29.11
- HLVX 41.18
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.